Johnson & Johnson (JNJ) plans to appeal a ruling by China's State Administration for Industry & Commerce (SAIC) to cancel the company's exclusive rights to the trademark for its OneTouch diabetes monitoring products.
If upheld, SAIC's decision could pave the way for competitors to sell rival and cheaper products under the same name.
China has around 100M diabetes sufferers, the largest number in the world.
Separately, J&J has asked the FDA to require that biosimilars, which are copies of biological treatments, bear a similar but not identical name to reference therapies.
In contrast, Novartis and Mylan want biosimilars to use the same international non-proprietary name.